Home > Compound List > Product Information
Bicalutamide_Molecular_structure_CAS_90357-06-5)
Click picture or here to close

Bicalutamide

Catalog No. DB01128 Name DrugBank
CAS Number 90357-06-5 Website http://www.ualberta.ca/
M. F. C18H14F4N2O4S Telephone (780) 492-3111
M. W. 430.3733728 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 999

SYNONYMS

IUPAC name
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorobenzenesulfonyl)-2-hydroxy-2-methylpropanamide
IUPAC Traditional name
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorobenzenesulfonyl)-2-hydroxy-2-methylpropanamide
Brand Name
Casodex

DATABASE IDS

PubChem SID 46505386
CAS Number 90357-06-5
PubChem CID 2375

PROPERTIES

Hydrophobicity(logP) 2.5
Solubility 5 mg/L

DETAILS

Description (English)
Item Information
Drug Groups approved
Description Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It binds to the androgen receptor.
Indication For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.
Pharmacology Bicalutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Bicalutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Bicalutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Affected Organisms
Humans and other mammals
Biotransformation Bicalutamide undergoes stereo specific metabolism. The S (inactive) isomer is metabolized primarily by glucuronidation. The R (active) isomer also undergoes glucuronidation but is predominantly oxidized to an inactive metabolite followed by glucuronidation.
Absorption Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown.
Half Life 5.9 days
Protein Binding 96%
Clearance * Apparent oral cl=0.32 L/h [Normal Males]
External Links
Wikipedia
RxList
Drugs.com

REFERENCES